{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:49:15Z","timestamp":1774950555162,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clinthera.2025.09.007","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:00:56Z","timestamp":1761591656000},"page":"1076-1079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recurrent Drug-induced Rhabdomyolysis in a 76-year-old Patient With Cystic Fibrosis: Drug\u2013Drug Interactions in Older Patients With Cystic Fibrosis"],"prefix":"10.1016","volume":"47","author":[{"given":"Elnatan","family":"Segal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Rabkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mordechai","family":"Muszkat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ido","family":"Sadras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oded","family":"Breuer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malena","family":"Cohen\u2013Cymberknoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yakov","family":"Fellig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anat","family":"Elazari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.09.007_bib0001","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.09.007_bib0002","first-page":"146","article-title":"Statin-associated rhabdomyolysis: is there a dose-response relationship?","volume":"27","author":"Holbrook","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.clinthera.2025.09.007_bib0003","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2025.09.007_bib0004","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"for the Immune-Mediated Necrotizing Myopathies Working Group. 224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.clinthera.2025.09.007_bib0005","first-page":"192","article-title":"Elexacaftor-tezacaftor-ivacaftor: the first triple-combination cystic fibrosis transmembrane conductance regulator modulating therapy","volume":"25","author":"Ridley","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2025.09.007_bib0006","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.clinthera.2025.09.007_bib0007","series-title":"Trikafta [package insert]","year":"2024"},{"key":"10.1016\/j.clinthera.2025.09.007_bib0008","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jcf.2023.01.005","article-title":"Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: focus on Trikafta\u00ae\/Kaftrio\u00ae","volume":"22","author":"Purkayastha","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.clinthera.2025.09.007_bib0009","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3390\/pharmaceutics17030318","article-title":"Evaluation of complex drug interactions between elexacaftor-tezacaftor-ivacaftor and statins using physiologically based pharmacokinetic modeling","volume":"17","author":"Hong","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clinthera.2025.09.007_bib0010","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1345\/aph.1H423","article-title":"Proposal for a new tool to evaluate drug interaction cases","volume":"41","author":"Horn","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2025.09.007_bib0011","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/bcp.13515","article-title":"Rhabdomyolysis after co-administration of a statin and fusidic acid: an analysis of the literature and of the WHO database of adverse drug reactions","volume":"84","author":"Deljehier","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2025.09.007_bib0012","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0924-8579(98)00071-5","article-title":"Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics","volume":"12","author":"Turnidge","year":"1999","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2025.09.007_bib0013","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1128\/AAC.01335-16","article-title":"Fusidic acid inhibits hepatic transporters and metabolic enzymes: potential cause of clinical drug-drug interaction observed with statin coadministration","volume":"60","author":"Gupta","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2025.09.007_bib0014","doi-asserted-by":"crossref","first-page":"e6562","DOI":"10.1136\/bmj.e6562","article-title":"for the Northern Ireland Neurology Network. Rhabdomyolysis after co-prescription of statin and fusidic acid","volume":"345","author":"Kearney","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2025.09.007_bib0015","first-page":"357","article-title":"Acute toxin-mediated rhabdomyolysis during treatment with trimethoprim-sulfamethoxazole","volume":"3","author":"Sperandeo","year":"2019","journal-title":"Clin Pract Cases Emerg Med"},{"key":"10.1016\/j.clinthera.2025.09.007_bib0016","unstructured":"Lexicomp Online, Drug Interactions. Wolters Kluwer Health, Inc. https:\/\/www.uptodate.com. Accessed July 22, 2025."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825003182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825003182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:55:08Z","timestamp":1774947308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825003182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0149291825003182"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.09.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrent Drug-induced Rhabdomyolysis in a 76-year-old Patient With Cystic Fibrosis: Drug\u2013Drug Interactions in Older Patients With Cystic Fibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}